TD Cowen analyst Tara Bancroft has maintained their bullish stance on XNCR stock, giving a Buy rating on October 29.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tara Bancroft’s rating is based on several promising developments within Xencor’s oncology and autoimmune pipelines. The company has shown encouraging results with its XmAb819 program, particularly in patients with heavily pre-treated clear cell renal cell carcinoma, achieving a 25% objective response rate which is competitive compared to existing therapies. This progress is complemented by ongoing enrollment in other key studies, such as the Phase IIb trial for XmAb942 and the Phase Ib study for plamotamab in rheumatoid arthritis.
Moreover, Xencor is actively addressing previous dosing challenges by retraining sites and developing a new formulation to improve treatment consistency. The anticipation of pivotal trials in 2027 for both XmAb819 and XmAb541, along with the near-term clinical entry of other bispecific antibodies, underscores the company’s robust pipeline and potential for future growth, justifying the Buy rating.
According to TipRanks, Bancroft is a 4-star analyst with an average return of 16.6% and a 48.45% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Geron, and Ocular Therapeutix.
In another report released on October 29, Barclays also upgraded the stock to a Buy with a $23.00 price target.